Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study. (Q38677010)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

title

Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

multicenter clinical trial

25 March 2020

main subject

0 references

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Silvana Guerriero

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Matteo Becatti

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Claudia Fabiani

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Florenzo Iannone

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Luca Cantarini

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1

Giuseppe Lopalco

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

6

Elena Silvestri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

10

Bruno Frediani

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

author name string

Stefano Gentileschi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Antonio Vitale

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Iacopo Cavallo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

publication date

21 February 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

page(s)

1031-1035

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease

25 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

Behçet's syndrome: disease manifestations, management, and advances in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

Evaluation of current therapeutic strategies in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

Effect of infliximab in progressive neuro-Behçet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

Adalimumab for the treatment of Behçet's disease: experience in 19 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

Safety and efficacy of etanercept in children with juvenile-onset Behcets disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

The Behcet's disease activity index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

EULAR recommendations for the management of Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

Behçet Disease-associated Uveitis Successfully Treated with Golimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

Cytokines and Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

Anakinra treatment in drug-resistant Behcet’s disease: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14397595.2017.1285857

10.1080/14397595.2017.1285857

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28712320%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference